Published online before print November 29, 2004, doi: 10.1161/01.STR.0000149628.80251.b8
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:74.)
© 2005 American Heart Association, Inc.
Original Contributions |
Safety and Feasibility of Recombinant Factor VIIa for Acute Intracerebral Hemorrhage
From the Departments of Neurology and Neurosurgery (S.M.), Columbia University College of Physicians and Surgeons, New York, NY; Novo Nordisk A/S (N.B.), Bagsvaerd, Denmark; the University of Cincinnati Medical Center (J.B.), Cincinnati, Ohio; Royal Melbourne Hospital (S.D.), University of Melbourne, Melbourne, Australia; Washington University School of Medicine (M.D.), St. Louis, Mo; Novo Nordisk (B.S.), Princeton, NY; and the University of Heidelberg (T.S.), Heidelberg, Germany.
Correspondence to Dr Stephan A. Mayer, Neurological Institute, 710 West 168th Street, Box 39, New York, NY 10032. E-mail sam14{at}columbia.edu
Background and Purpose— Hematoma growth occurs in 38% of intracerebral hemorrhage (ICH) patients scanned by computed tomography (CT) within 3 hours of onset. Activated recombinant factor VII (rFVIIa) promotes hemostasis at sites of vascular injury and may minimize hematoma growth after ICH.
Methods— In this randomized, double-blind, placebo-controlled, dose-escalation trial, 48 subjects with ICH diagnosed within 3 hours of onset were treated with placebo (n=12) or rFVIIa (10, 20, 40, 80, 120, or 160 µg/kg; n=6 per group). The primary endpoint was the frequency of adverse events (AEs). Safety assessments included serial electrocardiography (ECG), troponin I and coagulation testing, lower extremity Doppler ultrasonography, and calculation of edema:ICH volume ratios.
Results— Mean age was 61 years (range, 30 to 93) and 57% were male. At admission, mean National Institutes of Health Stroke Scale (NIHSS) score was 14 (range, 1 to 26), median Glasgow Coma Scale score was 14 (range, 6 to 15), and mean ICH volume was 21 mL (range, 1 to 151). Mean time from onset to treatment was 181 minutes (range, 120 to 265). Twelve serious AEs occurred, including 5 deaths (mortality 11%). Six AEs were considered possibly treatment-related, including rash, vomiting, fever, ECG T-wave inversion, and 2 cases of deep vein thrombosis (placebo and 20-µg/kg groups). No myocardial ischemia, consumption coagulopathy, or dose-related increase in edema:ICH volume occurred.
Conclusion— This small phase II trial evaluated a wide range of rFVIIa doses in acute ICH and raised no major safety concerns. Larger studies are justified to determine whether rFVIIa can safely and effectively limit ICH growth.
Key Words: cerebral hemorrhage • coagulation • emergency medical services • fibrinolysis • stroke
This article has been cited by other articles:
 |
|
 |
|
  R. Dutton, C. Hauser, K. Boffard, J. Dimsitts, G. Bernard, J. Holcomb, A. Leppaniemi, B. Tortella, B. Bouillon, and CONTROL Steering Committee Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding Clinical Trials, October 1, 2009; 6(5): 467 - 479. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Culley, S. Guttendorf, M. Coldren, S. J. Skledar, P. R. Gross, R. M. Spiro, D. J. Triulzi, and M. V. Ragni Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery Am. J. Health Syst. Pharm., September 1, 2009; 66(17): 1554 - 1559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Delgado Almandoz, A. J. Yoo, M. J. Stone, P. W. Schaefer, J. N. Goldstein, J. Rosand, A. Oleinik, M. H. Lev, R. G. Gonzalez, and J. M. Romero Systematic Characterization of the Computed Tomography Angiography Spot Sign in Primary Intracerebral Hemorrhage Identifies Patients at Highest Risk for Hematoma Expansion: The Spot Sign Score Stroke, September 1, 2009; 40(9): 2994 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-Y. Chen, C.-H. Tai, W. Tsay, P.-Y. Chen, and H.-F. Tien Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia Ann. Onc., June 1, 2009; 20(6): 1100 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Xue, Y. Fan, S. Liu, D. A. Zygun, A. Demchuk, and V. W. Yong Contributions of multiple proteases to neurotoxicity in a mouse model of intracerebral haemorrhage Brain, January 1, 2009; 132(1): 26 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bordes, Y. Asencio, N. Kenane, J. Fesselet, E. Meaudre, and P. Goutorbe Recombinant activated factor VII for acute subdural haematoma in an elderly patient taking fondaparinux Br. J. Anaesth., October 1, 2008; 101(4): 575 - 576. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Hardy, S. Belisle, and P. Van der Linden Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials Ann. Thorac. Surg., September 1, 2008; 86(3): 1038 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hallevi, K. C. Albright, J. Aronowski, A. D. Barreto, S. Martin-Schild, A. M. Khaja, N. R. Gonzales, K. Illoh, E. A. Noser, and J. C. Grotta Intraventricular hemorrhage: Anatomic relationships and clinical implications Neurology, March 11, 2008; 70(11): 848 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Diringer, B. E. Skolnick, S. A. Mayer, T. Steiner, S. M. Davis, N. C. Brun, and J. P. Broderick Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage Stroke, March 1, 2008; 39(3): 850 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hallevi, N. R. Gonzales, A. D. Barreto, S. Martin-Schild, K. C. Albright, E. A. Noser, K. Illoh, A. M. Khaja, T. Allison, M. A. Escobar, et al. The Effect of Activated Factor VII for Intracerebral Hemorrhage Beyond 3 Hours Versus Within 3 Hours Stroke, February 1, 2008; 39(2): 473 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Siao, A. Seetapah, A. Ryman, V. Guerin, A. Mesli, and P. Maurette Optimal Management of an Aneurysmal Subarachnoid Hemorrhage in a Patient With Known Factor XI Deficiency: A Case Report Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 108 - 111. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. REPRINT: Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation, October 16, 2007; 116(16): e391 - e413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Broderick, S. Connolly, E. Feldmann, D. Hanley, C. Kase, D. Krieger, M. Mayberg, L. Morgenstern, C. S. Ogilvy, P. Vespa, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage in Adults: 2007 Update: A Guideline From the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke, June 1, 2007; 38(6): 2001 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wada, R. I. Aviv, A. J. Fox, D. J. Sahlas, D. J. Gladstone, G. Tomlinson, and S. P. Symons CT Angiography "Spot Sign" Predicts Hematoma Expansion in Acute Intracerebral Hemorrhage Stroke, April 1, 2007; 38(4): 1257 - 1262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Thanvi and T. Robinson Sporadic cerebral amyloid angiopathy--an important cause of cerebral haemorrhage in older people Age Ageing, November 1, 2006; 35(6): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sugg, N. R. Gonzales, D. E. Matherne, M. Ribo, H. M. Shaltoni, S. Baraniuk, E. A. Noser, and J. C. Grotta Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology, September 26, 2006; 67(6): 1053 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Davis, J. Broderick, M. Hennerici, N. C. Brun, M. N. Diringer, S. A. Mayer, K. Begtrup, T. Steiner, and for the Recombinant Activated Factor VII Intracere Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage Neurology, April 25, 2006; 66(8): 1175 - 1181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Bishop, W. E.P. Renwick, C. Hogan, M. Haeusler, A. Tuckfield, and J. Tatoulis Recombinant Activated Factor VII: Treating Postoperative Hemorrhage in Cardiac Surgery Ann. Thorac. Surg., March 1, 2006; 81(3): 875 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Foerch, I Curdt, B Yan, F Dvorak, M Hermans, J Berkefeld, A Raabe, T Neumann-Haefelin, H Steinmetz, and M Sitzer Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke J. Neurol. Neurosurg. Psychiatry, February 1, 2006; 77(2): 181 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Huttner, T. Steiner, M. Hartmann, M. Kohrmann, E. Juettler, S. Mueller, J. Wikner, U. Meyding-Lamade, P. Schramm, S. Schwab, et al. Comparison of ABC/2 Estimation Technique to Computer-Assisted Planimetric Analysis in Warfarin-Related Intracerebral Parenchymal Hemorrhage Stroke, February 1, 2006; 37(2): 404 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Hoots Challenges in the Therapeutic Use of a "So-Called" Universal Hemostatic Agent: Recombinant Factor VIIa Hematology, January 1, 2006; 2006(1): 426 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Goldstein, S. H. Thomas, V. Frontiero, A. Joseph, C. Engel, R. Snider, E. E. Smith, S. M. Greenberg, and J. Rosand Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage Stroke, January 1, 2006; 37(1): 151 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cordonnier From Trials to "Real Life": Necessity of Efficacy Stroke, December 1, 2005; 36(12): 2527 - 2527. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Kase Hemostatic Treatment in the Early Stage of Intracerebral Hemorrhage: The Recombinant Factor VIIa Experience Stroke, October 1, 2005; 36(10): 2321 - 2322. [Full Text] [PDF]
|
|
|
|
|
|
E B Ringelstein Ultrafast magnetic resonance imaging protocols in stroke J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 905 - 905. [Full Text] [PDF]
|
|
|
|
|
|
J. P. Broderick The STICH Trial: What Does It Tell Us and Where Do We Go From Here? Stroke, July 1, 2005; 36(7): 1619 - 1620. [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Friedrich, K. N. Sheth, S. A. Mayer, and N. C. Brun Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage N. Engl. J. Med., May 19, 2005; 352(20): 2133 - 2134. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Lam and R. P Sims-McCallum Recombinant Factor VIIa in the Treatment of Non-Hemophiliac Bleeding Ann. Pharmacother., May 1, 2005; 39(5): 885 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Mayer, N. C. Brun, K. Begtrup, J. Broderick, S. Davis, M. N. Diringer, B. E. Skolnick, T. Steiner, and the Recombinant Activated Factor VII Intracerebral Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage N. Engl. J. Med., February 24, 2005; 352(8): 777 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Brown and L. B. Morgenstern Stopping the Bleeding in Intracerebral Hemorrhage N. Engl. J. Med., February 24, 2005; 352(8): 828 - 830. [Full Text] [PDF]
|
|